Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

ConclusionIn this study, reduction in CV risk and HbA1c change were the key drivers of GLP-1 RA medication preference in Japanese patients with T2D. Overall, the majority of the patients preferred a product with attribute levels reflecting the semaglutide 0.50  mg profile, with a known CV risk reduction benefit and superior HbA1c reduction.FundingNovo Nordisk.

Source: Diabetes Therapy - March 6, 2019 Category: Endocrinology Source Type: research